Treatment‐naïve patients with EGFR/ALK wild type Stage IV NSCLC were split into three equal groups and given the respective treatments: (A) Durvalumab + chemotherapy followed by durvalumab until the cancer progressed, (B) Durvalumab and tremelimumab along with chemotherapy, followed by durvalumab until cancer progression, with an additional dose of tremelimumab after chemotherapy and (C) Only chemotherapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.